J. Pers. Med. 2014, 4(1), 79-87; doi:10.3390/jpm4010079
Commentary

DTC-and-Me: Patient, Provider, Proteins and Regulators

* email and email
Received: 13 December 2013; in revised form: 6 March 2014 / Accepted: 7 March 2014 / Published: 18 March 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The yet-unrealized potential for more “personalized” Direct-to-Consumer (DTC) tests to fundamentally alter the practice and economics of healthcare is undeniable. However, there are also many challenges to be met, including the herculean task of ensuring that the information provided by such tests is scientifically sound and, ideally, medically actionable. We consider recent events in DTC testing and suggest a “thought experiment” of an approach that could ultimately meet the needs of patients, providers and regulatory authorities.
Keywords: proteomics; personalized medicine; SOMAmer; aptamer; SOMAscan; diagnostics; direct-to-consumer
PDF Full-text Download PDF Full-Text [733 KB, uploaded 18 March 2014 09:25 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Steele, F.R.; Gold, L. DTC-and-Me: Patient, Provider, Proteins and Regulators. J. Pers. Med. 2014, 4, 79-87.

AMA Style

Steele FR, Gold L. DTC-and-Me: Patient, Provider, Proteins and Regulators. Journal of Personalized Medicine. 2014; 4(1):79-87.

Chicago/Turabian Style

Steele, Fintan R.; Gold, Larry. 2014. "DTC-and-Me: Patient, Provider, Proteins and Regulators." J. Pers. Med. 4, no. 1: 79-87.

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert